



Available online at <http://scik.org>

Commun. Math. Biol. Neurosci. 2023, 2023:109

<https://doi.org/10.28919/cmbn/8162>

ISSN: 2052-2541

## A STUDY OF FRACTIONAL BOVINE TUBERCULOSIS MODEL WITH VACCINATION ON HUMAN POPULATION

BOUBACAR DIALLO<sup>1,\*</sup>, JECONIA ABONYO OKELO<sup>2</sup>, SHAIBU OSMAN<sup>3</sup>, SIMON KARANJA<sup>2</sup>,  
NNAEMEKA STANLEY AGUEGBOH<sup>2</sup>

<sup>1</sup>Department of Mathematics, Pan African University, Institute for Basic Science, Technology and Innovation  
PAUSTI, Nairobi, Kenya

<sup>2</sup>Jomo Kenyatta University of Agriculture and Technology JKUAT, Nairobi, Kenya

<sup>3</sup>Department of Basic Sciences, University of Health and Allied Sciences, Ho, Ghana

Copyright © 2023 the author(s). This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Abstract.** A bacterial and zoonotic disease called bovine tuberculosis (bTB) can be contracted by breathing in aerosols, consuming unpasteurized milk, or eating raw meat. The evolution of bovine tuberculosis transmission in both human and animal populations is investigated in this research using a fractional order model with caputo sensing and a compartment for human vaccination. The threshold quantity  $R_0$  was also constructed using Volterra-type Lyapunov functions, LaSalle's invariance principle, and the Routh-Hurwitz criterion to identify the sick state and provide conditions that guarantee the local and global asymptotic stability of the equilibria. In order to determine the variables that control the dynamics of bTB, we performed a sensitivity study. The analysis indicates that factors influencing the spread of bTB include the rate of environmental contamination, the rate of bTB transmission from animal to animal, and the rate at which bTB is contracted by people from infected animals and the environment. However, the disease becomes less common in humans as vaccination rates rise and consumption of the contaminated environment's products (meat and dairy products) declines. For the management of bTB, it is recommended to implement educational initiatives, monitor the environment, treat affected individuals, administer

---

\*Corresponding author

E-mail address: [diallo.boubacar@students.jkuat.ac.ke](mailto:diallo.boubacar@students.jkuat.ac.ke)

Received August 05, 2023

immunizations, and confine contaminated animals. Numerical experiments are used to show how useful the found theoretical results are.

**Keywords:** fractional order model; zoonotic disease; bovine tuberculosis; vaccination compartment.

**2020 AMS Subject Classification:** 92C60.

## 1. INTRODUCTION

In recent years, Africa has made strides in the fight against tuberculosis (TB), but numerous challenges still stand in the way of efforts to eradicate this avoidable and treatable illness. Global efforts to eradicate the illness by 2030 appear to be lagging behind schedule at the present time [1, 2]. Tuberculosis (TB) is a chronic infectious illness that mostly affects the respiratory system. Africa had the highest cases, followed by India, China, and Indonesia in order of prevalence, with 72%, 27%, 9%, and 8%, respectively, according to studies in [3].

COVID-19 has an effect on both TB research and the relationship between TB and care. The reallocation of resources to the COVID-19 response has made it more difficult for numerous countries to provide essential services. Many people with tuberculosis have had trouble getting treatment because of the lockdowns. COVID-19 has an impact on the ability to identify drug-resistant tuberculosis, according to World Health. In 2020, there were 28% fewer cases recorded in the WHO's African Region than there were in 2019[1].

Bovine tuberculosis is a zoonotic infectious disease that the OIE (Office International des Epizooties) designates as a class *B* animal pandemic. Infected animals can be the main source of infection for both humans and other animals. The main pathways of transmission are the gut and respiratory systems. Healthy people and animals can become infected by sick animals by coming into contact with them or drinking their raw milk, [4], [5]. The disease has a major negative economic impact due to the slaughter of bTB-infected animals when they become ill. [5]. Furthermore, bTB has a negative impact on people's health, which can occasionally result in fatalities [6]. It may lead to the loss of their self-employment for some employees, particularly those who depend on raising cattle as their main source of income [7]. Inhaling aerosols, consuming raw meat, and drinking unpasteurized milk are the three main ways that bovine tuberculosis spreads from animals to humans. Additional methods that bTB spreads

among animals include intimate contact between infected and uninfected animals, consumption of contaminated milk, particularly during lactation, and inhalation of aerosols [8] [9].

The most well-known and often employed method for diagnosing bTB is the intradermal skin test [10]. According to numerous articles, its main shortcomings are its varying sensitivity and specificity. Additionally, tuberculosis vaccination techniques hinder this test since sensitized animals produce false-positive results [9]. A deterministic mathematical model is developed in [5] to investigate the dynamics of bTB transmission in people and animals living in contaminated environments. The fundamental reproduction number  $R_0$  is determined to ascertain the disease's behavior. According to the sensitivity analysis, the rate of production of dairy products, the rate of bTB transmission from animal to animal, and the rate at which humans contract bTB from infected dairy products and animals are what propel bTB transmission.

An intriguing article [11] evaluates the effects of the BCG vaccination on cattle and is based on a meta-analysis by experts from Ethiopia, the Netherlands, the United States, the United Kingdom, and India. In endemic locations, BCG vaccination may speed the control of bTB, according to their findings. The immunology of *Mycobacterium bovis* (Mb) infection has been covered in some papers. Lung and lymph node lesions, which ultimately lead to the formation of granulomas, define the pathophysiology of bovine TB. The chronic development and immunopathology of bTB have many characteristics with those of human TB, according to a new study by Blanco [9]. Ahmad, Khan, Ahmad, Stanimirovic, and Chu in [12] created the reaction-diffusion model and used the fractional differential equation to derive standard solutions to the nonlinear partial differential equation. The fractional differential equation, which may be used in a variety of contexts, is an effective tool for comprehending the dynamics of diverse life events in fractional order.

In [13], differential equations of integer and fractional orders are used to build mathematical models for the dynamics of Potato Leaf Roll Virus propagation. The models considered both the Potato and Vector populations. The potato leaf roll virus (PLRV) model was initially proposed in integer order, and it was then extended into fractional order since fractional order provides memory and other benefits for replicating actual events.

Review of fractional epidemic models is the title of a publication by Chen et al[14]. that focuses on reviewing various fractional epidemic model types and evaluating the results of epidemiological modeling, particularly the fractional epidemic model. To address fractional epidemic models, they created straightforward and efficient analytical procedures that may be readily expanded and applied to other fractional models. These methods can help the concerned organizations stop, manage, and even predict infectious disease epidemics.

To the authors' knowledge, no studies have been conducted to model the transmission of bovine TB using classes for vaccination and contaminated environment. Therefore, this paper created a fractional-order mathematical model of bovine TB by accounting for vaccination and a contaminated environment. According to the findings, lowering the infection rate  $\sigma_A$  and contact rate  $\sigma_H$  significantly aids in the management of the TB disease in animal human population respectively. Additionally, disinfecting by warming the dairy products and cooking very well the meat has a significant positive impact on the disease's control. This is because it increases the elimination rate of contaminated environment  $\omega$ .

This paper is organized as follows: In Section 2, the formulation and outline of the suggested model are presented. Section 3's primary objective is the model's analysis. Section 4 covers the numerical simulation of the model. Section 5 concludes with a summary and recommendations.

## 2. MODEL DESCRIPTION AND FORMULATION

According to their disease condition in the system, the model separates the overall human and animal populations into seven (7) sub-populations (compartments) at any given time (t), and another compartment for the contaminated environment  $C_e$ .

We have the following assumptions:

- (1) It is assumed that birth rates and immigration rates into the susceptible human population are stable.
- (2) The direct transmission between people, between people and animal, and between animals follows the usual occurrence.
- (3) The model does not have a recovery class because it is presumed that there is no natural recovery.

- (4) It is believed that after contracting bTB, people or animals take some time before developing clinical symptoms.
- (5) Humans can catch the disease by consuming dairy products and meat from infected animals.

The sub-populations of Susceptible animal ( $S_A$ ), Exposed animal ( $E_A$ ), and Infectious animal ( $I_A$ ) make up the overall animal population, denoted by  $\Omega_A(t)$ .

The total Animal population becomes:

$$\Omega_A(t) = S_A(t) + E_A(t) + I_A(t).$$

The total human population also represented by  $\Omega_H$ , is divided into sub-populations of Susceptible humans ( $S_H$ ), Vaccinated humans  $V_H$ , Exposed humans  $E_H$ , and Infected humans  $I_H$ .

The total human population is given by:

$$\Omega_H(t) = S_H(t) + V_H(t) + E_H(t) + I_H(t).$$

Our current model is formulated by modifying the bovine tuberculosis model for human and animal which was developed by [5] which have seven compartments.

**2.1. Model formulation.** The list of variables and parameters used are as below

Symbol	Definition
$S_H$	Susceptible human population
$E_H$	Exposed human population
$I_H$	Infected human population
$V_H$	Vaccinated human population
$S_A$	Susceptible animal population
$E_A$	Exposed animal population
$I_A$	Infected animal population
$C_e$	Contaminated environment

TABLE 1. Model Variables and their definitions for bovine TB

Humans who are susceptible to bovine tuberculosis are recruited through birth and migration at a rate of  $\Lambda_H$ , and they contract the latent infection through contact with infected humans and

animals as well as through consumption of raw meat and dairy products from infected animals at a rate of  $\Lambda_H$ .

$$(1) \quad \lambda_H = \frac{\eta_1 I_H + \eta_2 I_A + \eta_3 C_e}{\Omega_H}$$

A portion of people obtain effective immunizations at a rate of  $\kappa$ , with  $\kappa \in [0, 1]$ . The following latent infection of susceptible humans  $S_H$  is enhanced at a rate of  $\lambda_H$  by the exposed compartment  $E_H$  and decreased at a rate of  $\gamma_H$  by the advancement to the infectious stage. Due to disease-related deaths, human infections  $I_H$  grow at  $\gamma_H$  and diminish at  $\alpha_H$ .

Every human compartment is subject to natural death at a rate of  $\mu_H$ . Humans that have received vaccinations may transition to the exposed class at a pace of  $d\lambda_H$  due to the vaccine's effectiveness's decreasing impact with  $(1 - d) \in [0, 1]$ . Humans may become susceptible and lose their immunity at a rate of  $\phi$ .

At a rate of  $\Lambda_A$ , susceptible animals  $S_A$  are bred and migrated into populations, where they are latently infected with bovine tuberculosis through contact with diseased people and animals as well as dairy consumption.

$$(2) \quad \lambda_A = \frac{\eta_4 I_H + \eta_5 I_A + \eta_6 C_e}{\Omega_A}$$

After susceptible animals, exposed animals  $E_A$  increase at a rate of  $\lambda_A$  as  $S_A$  become latently infected. However, as they progress to the infectious stage, they begin to diminish at a rate of  $\gamma_A$ . Due to disease-induced death, infected animals  $I_A$  grow at a rate of  $\gamma_A$  and drop at a rate of  $\alpha_A$ .

Natural mortality occurs at a rate of  $\mu_A$  in every animal compartment. As sensitive humans and animals consume dairy products at rates of  $\eta_3$  and  $\eta_6$ , respectively, infected animals produce dairy products or raw meat at rate of  $\rho$  and leak them out at rate of  $\omega$ .

We will consider the fractional model using Caputo derivatives of order  $\alpha$  such that  $0 < \alpha < 1$ .




FIGURE 1. Schematic diagrams for bovine TB transmission among humans and animals

In our present work we will use Diethelm's approach [15], from Figure 1, we have the following system of fractional order equations:

(3)

$$\begin{aligned}
 {}_0^C D_t^\alpha S_H(t) &= (1 - \kappa^\alpha) \Lambda_H^\alpha + \phi^\alpha V_H - \left( \frac{\eta_1^\alpha I_H + \eta_2^\alpha I_A + \eta_3^\alpha C_e}{\Omega_H} \right) S_H - \mu_H^\alpha S_H, \\
 {}_0^C D_t^\alpha E_H(t) &= \left( \frac{\eta_1^\alpha I_H + \eta_2^\alpha I_A + \eta_3^\alpha C_e}{\Omega_H} \right) S_H + d \left( \frac{\eta_1^\alpha I_H + \eta_2^\alpha I_A + \eta_3^\alpha C_e}{\Omega_H} \right) V_H - (\mu_H^\alpha + \sigma_H^\alpha) E_H - \kappa^\alpha E_H, \\
 {}_0^C D_t^\alpha V_H(t) &= \kappa^\alpha \Lambda_H^\alpha + \kappa^\alpha E_H - (\mu_H^\alpha + \phi^\alpha) V_H - d \left( \frac{\eta_1^\alpha I_H + \eta_2^\alpha I_A + \eta_3^\alpha C_e}{\Omega_H} \right) V_H, \\
 {}_0^C D_t^\alpha I_H(t) &= \sigma_H^\alpha E_H - (\mu_H^\alpha + \gamma_H^\alpha) I_H, \\
 {}_0^C D_t^\alpha S_A(t) &= \Lambda_A^\alpha - \left( \frac{\eta_4^\alpha I_H + \eta_5^\alpha I_A + \eta_6^\alpha C_e}{\Omega_A} \right) S_A - \mu_A^\alpha S_A, \\
 {}_0^C D_t^\alpha E_A(t) &= \left( \frac{\eta_4^\alpha I_H + \eta_5^\alpha I_A + \eta_6^\alpha C_e}{\Omega_A} \right) S_A - (\mu_A^\alpha + \sigma_A^\alpha) E_A, \\
 {}_0^C D_t^\alpha I_A(t) &= \sigma_A^\alpha E_A - (\mu_A^\alpha + \gamma_A^\alpha) I_A, \\
 {}_0^C D_t^\alpha C_e(t) &= \rho^\alpha I_A - \omega^\alpha C_e
 \end{aligned}$$

with initial condition,

$$S_H(0) \geq 0, \quad E_H(0) \geq 0, \quad I_H(0) \geq 0, \quad V_H(0) \geq 0, \quad S_A(0) \geq 0, \quad E_A(0) \geq 0, \\ I_A(0) \geq 0, \quad C_e(0) \geq 0$$

where  ${}_0^C D^\alpha$  is the Caputo fractional derivative.

Note that, for simplification, in the following, we will use the notation  $D^\alpha$  instead of  ${}_0^C D^\alpha$ .

### 3. ANALYSIS OF THE MODEL

We look for invariant regions and evaluate the positivity of solutions to see if the model makes sense mathematically and epidemiologically. When the model's solutions are both positive and bounded, it becomes mathematically and biologically significant.

**3.1. Invariant Region.** The model solutions' viability is demonstrated by the invariant area. We use the initials  $\Omega_H$  and  $\Omega_A$  to represent the human and animal groups of individuals, respectively, to examine the viability of the model solutions.

**Theorem 3.1.** Let  $\Psi = \{(S_H(t), E_H(t), V_H(t), I_H(t), S_A(t), E_A(t), I_A(t), C_e(t)) \in \mathbb{R}_+^8 :$

$$0 \leq N_H \leq \frac{\Lambda_H}{\mu_H} \cup 0 \leq N_A \leq \frac{\Lambda_A}{\mu_A} \cup 0 \leq C_e \leq \frac{\Lambda_A \rho}{\mu_A \omega}\}$$

The feasible solution set  $\{(S_H(t), E_H(t), V_H(t), I_H(t), S_A(t), E_A(t), I_A(t), C_e(t))\}$  of the system equation of the model enter and bounded in the region  $\Psi$

*Proof of Theorem 3.1.* To prove this, let us consider the human population, animal population, and contaminated environment separately.

- The fractional derivative of the total human population, obtained by adding all the human equations of the model (3), is given by

$$N_H(t) = S_H(t) + E_H(t) + V_H(t) + I_H(t)$$

$$D^\alpha N_H = D^\alpha S_H + D^\alpha E_H + D^\alpha V_H + D^\alpha I_H$$

$$D^\alpha N_H = \Lambda_H^\alpha + \phi^\alpha V_H - \lambda_H^\alpha S_H - \kappa^\alpha S_H - \mu_H^\alpha S_H + \lambda_H^\alpha S_H - (\mu_H^\alpha + \sigma_H^\alpha) E_H$$

$$+ \kappa^\alpha (S_H + E_H) - \mu_H^\alpha V_H + \sigma_H^\alpha E_H - (\mu_H^\alpha + \gamma_H^\alpha) I_H$$

$$D^\alpha N_H = \Lambda_H^\alpha - \mu_H^\alpha S_H - \mu_H^\alpha E_H - \mu_H^\alpha V_H - \mu_H^\alpha I_H - \gamma_H^\alpha V_H - \gamma_H^\alpha I_H$$



$$(4) \quad D^\alpha N_H = \Lambda_H^\alpha - \mu_H^\alpha N_H - \gamma_H^\alpha I_H$$

$$(5) \quad D^\alpha N_H \leq \Lambda_H^\alpha - \mu_H^\alpha N_H$$

**Note:** To make simple the expressions, we'll do the calculations without  $\alpha$  on the right hand side.

Let us take the Laplace transform [16] of equation (4) on both sides:

$$(6) \quad \mathcal{L} \{D_t^\alpha N_H(t)\}(s) + \mathcal{L} \{\mu_H N_H(t)\}(s) \geq \mathcal{L} \{\Lambda_H\}(s)$$

On the LHS:

$$\mathcal{L} \{ {}_a D_t^\alpha N_H(t) \}(s) = s^\alpha \mathcal{N}_H(s) - \sum_{k=0}^{n-1} s^{\alpha-k-1} N_H^{(k)}(0), \quad n-1 < \alpha \leq n$$

Here  $0 < \alpha < 1$ , so  $n = 1$ ,

then,  $\mathcal{L} \{D_t^\alpha N_H(t)\}(s) = s^\alpha \mathcal{N}_H(s) - s^{\alpha-1} N_H(0)$ , and

$$\mathcal{L} \{\mu_H N_H(t)\}(s) = \mu_H \mathcal{N}_H(s)$$

On the RHS

$$\begin{aligned} \mathcal{L} \{\Lambda_H\}(s) &= \Lambda_H \mathcal{L}\{1\} \\ &= \frac{\Lambda_H}{s} \end{aligned}$$

Now the equation (6) becomes:

$$(7) \quad \mathcal{L} \{D_t^\alpha N_H(t)\}(s) + \mathcal{L} \{\mu_H N_H(t)\}(s) \geq \mathcal{L} \{\Lambda_H\}(s)$$

$$(8) \quad s^\alpha \mathcal{N}_H(s) - s^{\alpha-1} N_H(0) + \mu_H \mathcal{N}_H(s) \geq \frac{\Lambda_H}{s}$$

$$(9) \quad \mathcal{N}_H(s)(s^\alpha + \mu_H) \geq \frac{\Lambda_H}{s} + s^{\alpha-1} N_H(0)$$

$$(10)$$

Hence, take  $s^{\alpha-1}N_H(0) = 0$  at  $t = 0$ , [17]

then

$$(11) \quad \mathcal{N}_H(s) \geq \Lambda_H \frac{s^{-1}}{s^\alpha + \mu_H}$$

Taking the inverse Laplace transform of  $\mathcal{N}_H(s)$ , and by using the Mittag-Leffler function, we have:

$$\begin{aligned} N_H(t) &\leq \Lambda_H \mathcal{L}^{-1} \left\{ \frac{s^{-1}}{s^\alpha + \mu_H} \right\} \\ &\leq \Lambda_H t^\alpha E_{\alpha, \alpha+1}(-\mu_H t^\alpha) \\ &\leq \frac{\Lambda_H}{\mu_H} [1 - E_\alpha(-\mu_H t^\alpha)] \end{aligned}$$

$$(12) \quad N_H(t) \leq \frac{\Lambda_H}{\mu_H} [1 - E_\alpha(-\mu_H t^\alpha)]$$

We have  $\mu_H > 0$  and then, as  $t \rightarrow 0$ , thus  $N_H(t) \rightarrow \frac{\Lambda_H}{\mu_H} \geq 0$ . Therefore

$$(13) \quad 0 \leq N_H(t) \leq \frac{\Lambda_H}{\mu_H}$$

$$(14) \quad \Psi_H = \left\{ (S_H, E_H, V_H, I_H) \in \mathbb{R}_+^4 : S_H + E_H + V_H + I_H \leq \frac{\Lambda_H^\alpha}{\mu_H^\alpha} \right\}.$$

• By the same approach, for animal population, we'll get:

$$(15) \quad \Psi_A = \left\{ (S_A, E_A, I_A) \in \mathbb{R}_+^3 : S_A + E_A + I_A \leq \frac{\Lambda_A^\alpha}{\mu_A^\alpha} \right\}.$$

• For the case of contaminated environment:

$$(16) \quad D_t^\alpha C_e(t) = \rho^\alpha I_A - \omega^\alpha C_e,$$

with the assumption that  $0 < I_A \leq \frac{\Lambda_A^\alpha}{\mu_A^\alpha}$ .

Then we have from the equation (16)

$$(17) \quad D^\alpha C_e(t) \leq \rho^\alpha \frac{\Lambda_A^\alpha}{\mu_A^\alpha} - \omega^\alpha C_e$$

Now by taking the Laplace transform of the equation (17) on both sides and using the equality case, we have:

$$(18) \quad \mathcal{L}\{D_t^\alpha C_e(t)\}(s) \leq \mathcal{L}\left\{\left(\rho^\alpha \frac{\Lambda_A^\alpha}{\mu_A^\alpha} - \omega^\alpha C_e(t)\right)\right\}(s)$$

Following the same calculus approach in the human population case,  
On the LHS,

$$\mathcal{L}\{D_t^\alpha C_e(t)\}(s) = s^\alpha \mathcal{C}_e(s) - s^{\alpha-1} C_e(0),$$

On the RHS,

$$\begin{aligned} \mathcal{L}\left\{\left(\rho \frac{\Lambda_A}{\mu_A} - \omega C_e(t)\right)\right\}(s) &= \left(\rho \frac{\Lambda_A}{\mu_A}\right) \mathcal{L}\{1\} - \omega \mathcal{L}\{C_e(t)\} \\ &= \frac{\left(\rho \frac{\Lambda_A}{\mu_A}\right)}{s} - \omega \mathcal{C}_e(s) \end{aligned}$$

Now the equation (18) becomes:

$$(19) \quad \mathcal{C}_e(s) = \left(\rho \frac{\Lambda_A}{\mu_A}\right) \frac{s^{-1}}{s^\alpha + \omega} + \frac{s^{\alpha-1}}{s^\alpha + \omega} C_e(0)$$

Hence, take  $s^{\alpha-1} C_e(0) = 0$  at  $t = 0$ ,

then

$$(20) \quad \mathcal{C}_e(s) = \left(\rho \frac{\Lambda_A}{\mu_A}\right) \frac{s^{-1}}{s^\alpha + \omega}$$

Taking the inverse Laplace transform of (20), we have:

$$\begin{aligned} C_e(t) &= \left(\rho \frac{\Lambda_A}{\mu_A}\right) \mathcal{L}^{-1}\left\{\frac{s^{-1}}{s^\alpha + \omega}\right\} \\ &= \left(\rho \frac{\Lambda_A}{\mu_A}\right) t^\alpha E_{\alpha, \alpha+1}(-\omega t^\alpha) \end{aligned}$$

$$(21) \quad C_e(t) \leq \frac{\Lambda_A \rho}{\mu_A \omega} [1 - E_\alpha(-\omega t^\alpha)]$$

We have  $\omega > 0$  and then, as  $t \rightarrow 0$ , thus  $C_e(t) \rightarrow \frac{\Lambda_A \rho}{\mu_A \omega} \geq 0$ . Therefore

$$(22) \quad 0 \leq C_e(t) \leq \frac{\Lambda_A \rho}{\mu_A \omega}$$

and so

$$(23) \quad \Psi_{C_e} = \left\{C_e \in \mathbb{R}_+ : C_e \leq \frac{\Lambda_A^\alpha \rho^\alpha}{\mu_A^\alpha \omega^\alpha}\right\}$$

The feasible region for the system of fractional differential equations in (3) is given by:

$$(24) \quad \Psi = \Psi_H \times \Psi_A \times \Psi_{C_e} \subset \mathbb{R}_+^4 \times \mathbb{R}_+^3 \times \mathbb{R}_+,$$

which is a positive invariant set.

This shows the boundedness of the solution of the model.  $\square$

**3.2. Positivity of the Solution.** In this section, we showed all the solution of the models Equation (3) remains positive for future time if their respective initial values are positive.

To establish this second result, we introduce the following lemma.

**Lemma 3.1.** (*Generalized Mean Value Theorem*) [18]

Suppose that  $z(t) \in C[a, b]$  and  ${}_0^C D_t^\alpha z(t) \in C[a, b]$  for  $0 < \alpha \leq 1$ , then

$$(25) \quad z(t) = z(a) + \frac{1}{\Gamma(\alpha)} {}_0^C D_t^\alpha z(\eta) \cdot (t - a)^\alpha,$$

where  $a \leq \eta \leq t, \forall t \in (a, b]$ .

**Remark 3.1.** Assume that  $z(t) \in C[a, b]$  and  ${}_0^C D_t^\alpha z(t) \in C[a, b]$  for  $0 < \alpha \leq 1$ . It follows from Lemma (3.1) that if  ${}_0^C D_t^\alpha z(t) \geq 0, \forall t \in (a, b)$ , then  $z(t)$  is increasing for  $\forall t \in [a, b]$ , and if  ${}_0^C D_t^\alpha z(t) \leq 0, \forall t \in (a, b)$  then  $z(t)$  is decreasing for  $\forall t \in [a, b]$

**Theorem 3.2.** If  $S_H(0), E_H(0), V_H(0), I_H(0), S_A(0), E_A(0), I_A(0), C_e(0)$  are positives, then  $S_H(t), E_H(t), V_H(t), I_H(t), S_A(t), E_A(t), I_A(t), C_e(t)$  are also positives for all time  $t > 0$ ;

*Proof of theorem 3.2.* Let us take all the equations of the model in Equation (3) at  $t = 0$ , we have:

$$(26) \quad {}_0^C D_t^\alpha S_H|_{S_H=0} = (1 - \kappa^\alpha) \Lambda_H^\alpha + \phi^\alpha V_H \geq 0$$

$$(27) \quad {}_0^C D_t^\alpha E_H|_{E_H=0} = \lambda_H S_H + d \lambda_H V_H \geq 0$$

$$(28) \quad {}_0^C D_t^\alpha V_H|_{V_H=0} = \kappa^\alpha \Lambda_H^\alpha + \kappa^\alpha E_H \geq 0$$

$$(29) \quad {}_0^C D_t^\alpha I_H|_{I_H=0} = \sigma_H^\alpha E_H \geq 0$$

$$(30) \quad {}_0^C D_t^\alpha S_A|_{S_A=0} = \Lambda_A^\alpha > 0$$

$$(31) \quad {}_0^C D_t^\alpha E_A|_{E_A=0} = \lambda_A S_A \geq 0$$

$$(32) \quad {}_0^C D_t^\alpha I_A|_{I_A=0} = \sigma_A^\alpha E_A \geq 0$$

$$(33) \quad {}_0^C D_t^\alpha C_e|_{C_e=0} = \rho^\alpha I_A \geq 0$$

Since  $S_H(0), E_H(0), V_H(0), I_H(0), S_A(0), E_A(0), I_A(0), C_e(0)$  are positives, according to (26)-(33) and the remark (3.1), the solution  $(S_H(t), E_H(t), V_H(t), I_H(t), S_A(t), E_A(t), I_A(t), C_e(t))$  can't scape from the hyperplanes of  $S_H = 0, E_H = 0, V_H = 0, V_H = 0, I_H = 0, S_A = 0, E_A = 0, I_A = 0$ , and  $C_e = 0$ . Therefore, all the solutions of the model with initial conditions in  $\Psi$  remain in  $\Psi$  for all  $t > 0$ . Thus, this region is a positive invariant set.

The model (3) is mathematically and epidemiologically meaningful; therefore, we can consider the flow generated by the model for analysis.  $\square$

**3.3. Disease-Free Equilibrium (DFE), for the model of bTB.** The situation in which there are no diseases affecting the populace is known as the disease-free equilibrium point. According to  $\Phi_0$ , the disease-free equilibrium is established when bTB is absent from both the human and animal populations.

$$(34) \quad \begin{cases} {}_0^C D_t^\alpha S_H(t) = 0, \\ {}_0^C D_t^\alpha E_H(t) = 0, \\ {}_0^C D_t^\alpha V_H(t) = 0, \\ {}_0^C D_t^\alpha I_H(t) = 0, \\ {}_0^C D_t^\alpha S_A(t) = 0, \\ {}_0^C D_t^\alpha E_A(t) = 0, \\ {}_0^C D_t^\alpha I_A(t) = 0, \\ {}_0^C D_t^\alpha C_e(t) = 0 \end{cases}$$

After some calculus, we get:

$$(35) \quad \Phi_0 = \left( \frac{\Lambda_H^\alpha (\phi^\alpha + (1 - \kappa^\alpha) \mu_H^\alpha)}{\mu_H (\mu_H^\alpha + \phi^\alpha)}, 0, \frac{\kappa^\alpha \Lambda_H^\alpha}{\mu_H^\alpha + \phi^\alpha}, 0, \frac{\Lambda_A^\alpha}{\mu_A^\alpha}, 0, 0, 0 \right)$$

**3.4. The Basic Reproduction Number.** The basic reproduction number  $R_0$  describes the typical number of new cases that a single infectious person creates when they are introduced into a community that is completely susceptible [19, 20, 21]. It establishes if the illness spreads or

disappears in the community. When the fundamental reproduction number  $R_0$  is less than 1, the disease disappears from the population. If  $R_0$  is more than 1, the disease continues. This is true because the disease survives when an infectious person is brought to a community that is completely vulnerable to infection[22, 23].

To determine the basic reproduction number  $R_0$ , we use the next-generation matrix technique while accounting for new infections and transfer terms.[19, 22, 24]. The  $R_0$  is expressed as the greatest eigenvalue if the new infectious and transfer terms for bTB are indicated by  $F_i$  and  $V_i$ , respectively. We have,

$$R_0 = \rho(FV^{-1})$$

where

$$F = \left| \frac{\partial F_i x(0)}{\partial x_j} \right|, \quad V = \left| \frac{\partial V_i x(0)}{\partial x_j} \right|,$$

$\rho$  denotes here the spectral radius of a matrix which is the greatest eigenvalue of a given matrix.

We only take into account the infectious, the exposed, and contaminated environment classes in the system of fractional differential equations in (3) using the Next-Generation Matrix.

$$(36) \quad \begin{cases} {}^C_0 D_t^\alpha E_H(t) &= \lambda_H^\alpha S_H + d\lambda_H^\alpha V_H - (\mu_H^\alpha + \sigma_H^\alpha)E_H - \kappa^\alpha E_H, \\ {}^C_0 D_t^\alpha I_H(t) &= \sigma_H^\alpha E_H - (\mu_H^\alpha + \gamma_H^\alpha)I_H, \\ {}^C_0 D_t^\alpha E_A(t) &= \lambda_A^\alpha S_A - (\mu_A^\alpha + \sigma_A^\alpha)E_A, \\ {}^C_0 D_t^\alpha I_A(t) &= \sigma_A^\alpha E_A - (\mu_A^\alpha + \gamma_A^\alpha)I_A, \\ {}^C_0 D_t^\alpha C_e(t) &= \rho^\alpha I_A - \omega^\alpha C_e \end{cases}$$

Let  $F_i$  represent the number of new infections entering the system and  $V_i$  represent the number of infections leaving the system as a result of births or deaths.

$$F_i = \begin{bmatrix} \left( \frac{\eta_1^\alpha I_H + \eta_2^\alpha I_A + \eta_3^\alpha C_e}{\Omega_H} \right) S_H + d \left( \frac{\eta_1^\alpha I_H + \eta_2^\alpha I_A + \eta_3^\alpha C_e}{\Omega_H} \right) V_H \\ 0 \\ \left( \frac{\eta_4^\alpha I_H + \eta_5^\alpha I_A + \eta_6^\alpha C_e}{\Omega_A} \right) S_A \\ 0 \\ 0 \end{bmatrix}$$

$$V_i = \begin{bmatrix} (\mu_H^\alpha + \sigma_H^\alpha)E_H + \kappa^\alpha E_H \\ -\sigma_H^\alpha E_H + (\mu_H^\alpha + \gamma_H^\alpha)I_H \\ (\mu_A^\alpha + \sigma_A^\alpha)E_A \\ -\sigma_A^\alpha E_A + (\mu_A^\alpha + \gamma_A^\alpha)I_A \\ -\rho^\alpha I_A + \omega^\alpha C_e \end{bmatrix}$$

Now let's us express the jacobien matrix of  $F_i$  and  $V_i$  by  $F$  and  $V$  respectively.

$$F = \begin{bmatrix} 0 & \frac{\eta_1 S_H}{\Omega_H} + d \frac{\eta_1 V_H}{\Omega_H} & 0 & \frac{\eta_2 S_H}{\Omega_H} + d \frac{\eta_2 V_H}{\Omega_H} & \frac{\eta_3 S_H}{\Omega_H} + d \frac{\eta_3 V_H}{\Omega_H} \\ 0 & 0 & 0 & 0 & 0 \\ 0 & \frac{\eta_4 S_A}{\Omega_A} & 0 & \frac{\eta_5 S_A}{\Omega_A} & \frac{\eta_6 S_A}{\Omega_A} \\ 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 \end{bmatrix}$$

$$V = \begin{bmatrix} (\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha) & 0 & 0 & 0 & 0 \\ -\sigma_H^\alpha & (\mu_H^\alpha + \gamma_H^\alpha) & 0 & 0 & 0 \\ 0 & 0 & (\mu_A^\alpha + \sigma_A^\alpha) & 0 & 0 \\ 0 & 0 & -\sigma_A^\alpha & (\mu_A^\alpha + \gamma_A^\alpha) & 0 \\ 0 & 0 & 0 & 0 & -\rho^\alpha & \omega^\alpha \end{bmatrix}$$

$$V^{-1} = \begin{bmatrix} \frac{1}{(\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha)} & 0 & 0 & 0 & 0 \\ \frac{\sigma_H^\alpha}{(\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha)(\mu_H^\alpha + \gamma_H^\alpha)} & \frac{1}{(\mu_H^\alpha + \gamma_H^\alpha)} & 0 & 0 & 0 \\ 0 & 0 & \frac{1}{(\mu_A^\alpha + \sigma_A^\alpha)} & 0 & 0 \\ 0 & 0 & \frac{\sigma_A^\alpha}{(\mu_A^\alpha + \sigma_A^\alpha)(\mu_A^\alpha + \gamma_A^\alpha)} & \frac{1}{(\mu_A^\alpha + \gamma_A^\alpha)} & 0 \\ 0 & 0 & \frac{\rho^\alpha \sigma_A^\alpha}{(\mu_A^\alpha + \sigma_A^\alpha)(\mu_A^\alpha + \gamma_A^\alpha)\omega^\alpha} & \frac{\rho^\alpha}{(\mu_A^\alpha + \gamma_A^\alpha)\omega^\alpha} & \frac{1}{\omega^\alpha} \end{bmatrix}$$

**Note:** To simplify the claculus we'll make the folowing notations and leave  $\alpha$ , the order of derivative.

$$(37) \quad R_0 = FV^{-1} = \begin{bmatrix} A_1 & A_2 & A_3 & A_4 & A_5 \\ 0 & 0 & 0 & 0 & 0 \\ B_1 & B_2 & B_3 & B_4 & B_5 \\ 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 \end{bmatrix}$$

where,

$$\begin{aligned}
A_1 &= \frac{\eta_1 \sigma_H (dV_H + S_H)}{(\mu_H + \sigma_H + \kappa)(\mu_H + \gamma_H)} \\
A_2 &= \frac{dV_H \eta_1 + \eta_1 S_H}{\mu_H + \gamma_H} \\
A_3 &= \frac{(dV_H \eta_2 + \eta_2 S_H) \sigma_A}{(\mu_A + \gamma_A)(\mu_A + \sigma_A)} + \frac{(dV_H \eta_3 + \eta_3 S_H) \rho \sigma_A}{(\mu_A + \gamma_A)(\mu_A + \sigma_A) \omega} \\
A_4 &= \frac{dV_H \eta_2 + \eta_2 S_H}{\mu_A + \gamma_A} + \frac{(dV_H \eta_3 + \eta_3 S_H) \rho}{(\mu_A + \gamma_A) \omega} \\
A_5 &= \frac{d\eta_3 V_H + \eta_3 S_H}{\omega} \\
\\
B_1 &= \frac{\eta_4 \sigma_H S_A}{(\mu_H + \sigma_H + \kappa)(\mu_H + \gamma_H)} \\
B_2 &= \frac{\eta_4 S_A}{\mu_H + \gamma_H} \\
B_3 &= \frac{\eta_5 S_A \sigma_A}{(\mu_A + \gamma_A)(\mu_A + \sigma_A)} + \frac{\eta_6 S_A \rho \sigma_A}{(\mu_A + \gamma_A)(\mu_A + \sigma_A) \omega} \\
B_4 &= \frac{\eta_5 S_A}{\mu_A + \gamma_A} + \frac{\eta_6 S_A \rho}{(\mu_A + \gamma_A) \omega} \\
B_5 &= \frac{\eta_6 S_A}{\omega}
\end{aligned}$$

Now let us compute the eigenvalues of  $FV^{-1}$  and select the dominant eigenvalue.

Let  $X$  represent the eigenvalue of the matrix

$$(38) \quad \begin{vmatrix} A_1 - X & A_2 & A_3 & A_4 & A_5 \\ 0 & -X & 0 & 0 & 0 \\ B_1 & B_2 & B_3 - X & B_4 & B_5 \\ 0 & 0 & 0 & -X & 0 \\ 0 & 0 & 0 & 0 & -X \end{vmatrix} = 0$$

The equation (38) is equivalent to:

$$(39) \quad X^3 \begin{vmatrix} A_1 - X & A_3 \\ B_1 & B_3 - X \end{vmatrix} = 0$$

We have the following characteristic equation:

$$(40) \quad X^3 [X^2 - (A_1 + B_3)X + A_1 B_3 - A_3 B_1] = 0$$



The maximum eigenvalue is then:

$$(41) \quad \begin{aligned} X &= \frac{A_1 + B_3}{2} + \sqrt{\frac{(A_1 + B_3)^2 - 4(A_1 B_3 - A_3 B_1)}{4}} \\ X &= \frac{A_1 + B_3}{2} + \frac{\sqrt{(A_1 - B_3)^2 + 4A_3 B_1}}{2} \end{aligned}$$

Now let us evaluate  $A_1, A_3, B_1$  and  $B_3$  at the DFE  $\Phi_0$ :

$$A_1 = \frac{\eta_1 \sigma_H (d\kappa \mu_H - \kappa \mu_H + \phi + \mu_H)}{(\mu_H + \phi) (\mu_H + \sigma_H + \kappa) (\mu_H + \gamma_H)}$$

$$A_3 = \frac{\sigma_A (d\kappa \mu_H - \kappa \mu_H + \phi + \mu_H) (\omega \eta_2 + \rho \eta_3)}{(\mu_H + \phi) (\mu_A + \sigma_A) (\mu_A + \gamma_A) \omega}$$

$$B_1 = \frac{\eta_4 \sigma_H}{(\mu_H + \sigma_H + \kappa) (\mu_H + \gamma_H)}$$

$$B_3 = \frac{\sigma_A (\eta_5 \omega + \eta_6 \rho)}{(\mu_A + \sigma_A) (\mu_A + \gamma_A) \omega}$$

By substituting  $A_1, A_3, B_1$  and the  $B_3$ , we have:

$$(42) \quad R_1 = A_1 + B_3 = \frac{\eta_1 \sigma_H (d\kappa \mu_H - \kappa \mu_H + \phi + \mu_H)}{(\mu_H + \phi) (\mu_H + \sigma_H + \kappa) (\mu_H + \gamma_H)} + \frac{\sigma_A (\eta_5 \omega + \eta_6 \rho)}{(\mu_A + \sigma_A) (\mu_A + \gamma_A) \omega}$$

$$(43) \quad R_2 = A_1 - B_3 = \frac{\eta_1 \sigma_H (d\kappa \mu_H - \kappa \mu_H + \phi + \mu_H)}{(\mu_H + \phi) (\mu_H + \sigma_H + \kappa) (\mu_H + \gamma_H)} - \frac{\sigma_A (\eta_5 \omega + \eta_6 \rho)}{(\mu_A + \sigma_A) (\mu_A + \gamma_A) \omega}$$

$$(44) \quad R_3 = A_3 B_1 = \frac{\eta_4 \sigma_H \sigma_A (d\kappa \mu_H - \kappa \mu_H + \phi + \mu_H) (\omega \eta_2 + \rho \eta_3)}{\omega (\mu_H + \phi) (\mu_A + \sigma_A) (\mu_A + \gamma_A) (\mu_H + \sigma_H + \kappa) (\mu_H + \gamma_H)}$$

$$(45) \quad R_0 = \frac{R_1}{2} + \frac{\sqrt{R_2^2 + 4R_3}}{2}$$

In equation (42), the terms  $\frac{1}{(\mu_H + \sigma_H + \kappa)}$  and  $\frac{1}{(\mu_A + \sigma_A)}$  stand for the average amount of time each human and animal spend in their respective exposed classes,  $\frac{1}{(\mu_H + \phi)}$ , the average amount of time each human spend in the vaccinated class,  $\frac{1}{(\mu_H + \gamma_H)}$  and  $\frac{1}{(\mu_A + \gamma_A)}$  for the average amount of time

each infectious human and animal spend in their infectious classes,  $\frac{\eta_1 \sigma_H [\phi + \mu_H (1 + d\kappa - \kappa)]}{(\mu_H + \phi)(\mu_H + \gamma_H)(\mu_H + \sigma_H + \kappa)}$  is the percentage of infected humans who develop bTB and move from the exposed class to the infectious class after coming into contact with infectious humans and animals, respectively, and  $\frac{\sigma_A (\omega \eta_5 + \rho \eta_6)}{\omega (\mu_A + \gamma_A)(\mu_A + \sigma_A)}$  represents the overall proportion of diseased animals that pass from the exposed class to the infectious class as a result of interaction with infected animals and consumption of infectious dairy products.

The total of the proportions of infected people who contract bTB through contact with diseased animals and after ingesting infectious meat or dairy products is given by (43) :

$$\frac{\eta_4 \sigma_H \sigma_A (d\kappa \mu_H - \kappa \mu_H + \phi + \mu_H) (\omega \eta_2 + \rho \eta_3)}{\omega (\mu_H + \phi) (\mu_A + \sigma_A) (\mu_A + \gamma_A) (\mu_H + \sigma_H + \kappa) (\mu_H + \gamma_H)}.$$

**3.5. Local stability Analysis for Disease-Free Equilibrium (DFE).** To assess the local stability of a disease-free equilibrium when trace and determinant are used, we apply the linearization method like in [5]. If the eigenvalues of the Jacobien matrix are negative or have a negative real part, disease-free equilibrium is considered to be locally asymptotically stable.

**Theorem 3.3.** *If all of the eigenvalues of the  $J(\Phi_0)$  satisfy the requirement that  $|\arg \lambda_j| > \frac{\alpha \pi}{2}$ , where  $j = 1, 2, 3 \dots$ , and  $0 < \alpha \leq 1$ . Then  $\Phi_0$  is locally asymptotically stable.*

*Proof of theorem 3.3.* Taking the partial derivatives of each equation with respect to each variable, we get:

$$(46) \quad J(\mathbf{x}) = \begin{bmatrix} -\lambda_H^\alpha - \mu_H^\alpha & 0 & \phi^\alpha & -\frac{\eta_1^\alpha S_H}{\Omega_H} & 0 & 0 & -\frac{\eta_5^\alpha S_H}{\Omega_H} & -\frac{\eta_3^\alpha S_H}{\Omega_H} \\ \lambda_H^\alpha & -\mu_H^\alpha - \sigma_H^\alpha - \kappa^\alpha & d\lambda_H^\alpha & d\frac{\eta_1^\alpha S_H}{\Omega_H} & 0 & 0 & d\frac{\eta_2^\alpha S_H}{\Omega_H} & d\frac{\eta_3^\alpha S_H}{\Omega_H} \\ 0 & \kappa^\alpha & -\mu_H^\alpha - \phi^\alpha - d\lambda_H^\alpha & -d\frac{\eta_1^\alpha V_H}{\Omega_H} & 0 & 0 & -d\frac{\eta_2^\alpha V_H}{\Omega_H} & -d\frac{\eta_3^\alpha V_H}{\Omega_H} \\ 0 & \sigma_H^\alpha & 0 & -(\mu_H^\alpha + \gamma_H^\alpha) & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & -\frac{\eta_4^\alpha S_A}{N_A} & -\lambda_1^\alpha - \mu_A^\alpha & 0 & -\frac{\eta_5^\alpha S_A}{\Omega_A} & -\frac{\eta_6^\alpha S_A}{\Omega_A} \\ 0 & 0 & 0 & \frac{\eta_4^\alpha S_A}{\Omega_A} & \lambda_A^\alpha & -\mu_A - \sigma_A & \frac{\eta_5^\alpha S_A}{\Omega_A} & \frac{\eta_6^\alpha S_A}{\Omega_A} \\ 0 & 0 & 0 & 0 & 0 & \sigma_A^\alpha & -\mu_A^\alpha - \gamma_A^\alpha & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & \rho^\alpha & -\omega^\alpha \end{bmatrix}$$

where  $\mathbf{x} = [S_H, E_H, V_H, I_H, S_A, E_A, I_A, C_e]$  is the vector of variables, and  $J(\mathbf{x})_{ij}$  represents the partial derivative of the  $i$ -th equation with respect to the  $j$ -th variable.

After the Jacobian has been evaluated at DFE  $\Phi_0$ , we have

$$(47) \quad J(\Phi_0) = \begin{bmatrix} -\mu_H^\alpha & 0 & \phi^\alpha & \eta_1^\alpha & 0 & 0 & -\eta_2^\alpha & -\eta_3^\alpha \\ 0 & -\mu_H^\alpha - \sigma_H^\alpha - \kappa^\alpha & 0 & d\eta_1^\alpha & 0 & 0 & d\eta_2^\alpha & d\eta_3^\alpha \\ 0 & \kappa^\alpha & -\mu_H^\alpha - \phi^\alpha & -d\frac{\eta_1^\alpha \kappa^\alpha}{\mu_H^\alpha + \phi^\alpha} & 0 & 0 & -d\frac{\eta_2^\alpha \kappa^\alpha}{\mu_H^\alpha + \phi^\alpha} & -d\frac{\eta_3^\alpha \kappa^\alpha}{\mu_H^\alpha + \phi^\alpha} \\ 0 & \sigma_H^\alpha & 0 & -\mu_H^\alpha - \gamma_H^\alpha & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & -\eta_4^\alpha & -\mu_A^\alpha & 0 & -\eta_5^\alpha & -\eta_6^\alpha \\ 0 & 0 & 0 & \eta_4^\alpha & 0 & -\mu_A - \sigma_A & \eta_5^\alpha & \eta_6^\alpha \\ 0 & 0 & 0 & 0 & 0 & \sigma_A^\alpha & -\mu_A^\alpha - \gamma_A^\alpha & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & \rho^\alpha & -\omega^\alpha \end{bmatrix}$$

The Matrix (47) has negative eigenvalues  $-\mu_H^\alpha$ ,  $-\mu_A^\alpha$  and  $-\mu_H^\alpha - \phi^\alpha$ , and those three eigenvalues satisfy the condition:  $|\arg \lambda_j| > \frac{\alpha\pi}{2}$  for all  $0 < \alpha \leq 1$ .

Matrix (47) reduces now to:

$$(48) \quad R = \begin{bmatrix} -\mu_H^\alpha - \sigma_H^\alpha - \kappa^\alpha & d\eta_1^\alpha & 0 & d\eta_2^\alpha & d\eta_3^\alpha \\ \sigma_H^\alpha & -\mu_H^\alpha - \gamma_H^\alpha & 0 & 0 & 0 \\ 0 & \eta_4^\alpha & -\mu_A - \sigma_A & \eta_5^\alpha & \eta_6^\alpha \\ 0 & 0 & \sigma_A^\alpha & -\mu_A^\alpha - \gamma_A^\alpha & 0 \\ 0 & 0 & 0 & \rho^\alpha & -\omega^\alpha \end{bmatrix}$$

We employ trace  $tr$  and determinant  $det$  to examine matrix  $R$ . If the determinant is positive  $det(R) > 0$  and the trace is negative  $tr(R) < 0$ , then the disease-free equilibrium is locally stable.

The trace of the matrix  $R$  is given by:

$$(49) \quad tr(R) = -((\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha) + (\mu_H^\alpha + \gamma_H^\alpha) + (\mu_A + \sigma_A) + (\mu_A^\alpha + \gamma_A^\alpha) + \omega^\alpha) < 0$$

The determinant of  $R$  is given by:

$$(50) \quad det(R) = -(\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha) \begin{vmatrix} -\mu_H^\alpha - \gamma_H^\alpha & 0 & 0 & 0 \\ \eta_4^\alpha & -\mu_A - \sigma_A & \eta_5^\alpha & \eta_6^\alpha \\ 0 & \sigma_A^\alpha & -\mu_A^\alpha - \gamma_A^\alpha & 0 \\ 0 & 0 & \rho^\alpha & -\omega^\alpha \end{vmatrix}$$

$$\begin{aligned}
& -\sigma_H^\alpha \begin{vmatrix} d\eta_1^\alpha & 0 & d\eta_2^\alpha & d\eta_3^\alpha \\ \eta_4^\alpha & -\mu_A - \sigma_A & \eta_5^\alpha & \eta_6^\alpha \\ 0 & \sigma_A^\alpha & -\mu_A^\alpha - \gamma_A^\alpha & 0 \\ 0 & 0 & \rho^\alpha & -\omega^\alpha \end{vmatrix} \\
& = (\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha)(\mu_H^\alpha + \gamma_H^\alpha) [(\sigma_A^\alpha(\omega^\alpha \eta_5^\alpha + \rho^\alpha \eta_6^\alpha) - (\mu_A + \sigma_A)(\mu_A^\alpha + \gamma_A^\alpha)\omega^\alpha) \\
& \quad + \sigma_H^\alpha d\eta_1^\alpha (\mu_A + \sigma_A)(\mu_A^\alpha + \gamma_A^\alpha)\omega^\alpha + d\sigma_H^\alpha \sigma_A^\alpha [\omega^\alpha(\eta_2^\alpha \eta_4^\alpha - \eta_1^\alpha \eta_5^\alpha) + \rho^\alpha(\eta_3^\alpha \eta_4^\alpha - \eta_1^\alpha \eta_6^\alpha)]]
\end{aligned}$$

Let  $\det(R) = 0$  then,

(51)

$$\begin{aligned}
0 & = \sigma_A^\alpha (\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha)(\mu_H^\alpha + \gamma_H^\alpha)(\omega^\alpha \eta_5^\alpha + \rho^\alpha \eta_6^\alpha) \\
& \quad - (\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha)(\mu_H^\alpha + \gamma_H^\alpha)(\mu_A + \sigma_A)(\mu_A^\alpha + \gamma_A^\alpha)\omega^\alpha + \sigma_H^\alpha d\eta_1^\alpha (\mu_A + \sigma_A)(\mu_A^\alpha + \gamma_A^\alpha)\omega^\alpha \\
& \quad + d\sigma_H^\alpha \sigma_A^\alpha [\omega^\alpha(\eta_2^\alpha \eta_4^\alpha - \eta_1^\alpha \eta_5^\alpha) + \rho^\alpha(\eta_3^\alpha \eta_4^\alpha - \eta_1^\alpha \eta_6^\alpha)] \\
& = \frac{\sigma_A^\alpha(\omega^\alpha \eta_5^\alpha + \rho^\alpha \eta_6^\alpha)}{(\mu_A + \sigma_A)(\mu_A^\alpha + \gamma_A^\alpha)} + \frac{\sigma_H^\alpha d\eta_1^\alpha \omega^\alpha}{(\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha)} \\
& \quad + \frac{d\sigma_H^\alpha \sigma_A^\alpha [\omega^\alpha(\eta_2^\alpha \eta_4^\alpha - \eta_1^\alpha \eta_5^\alpha) + \rho^\alpha(\eta_3^\alpha \eta_4^\alpha - \eta_1^\alpha \eta_6^\alpha)]}{(\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha)(\mu_H^\alpha + \gamma_H^\alpha)(\mu_A + \sigma_A)(\mu_A^\alpha + \gamma_A^\alpha)\omega^\alpha} - 1
\end{aligned}$$

Thus  $\det(R) > 0$  if

$$(52) \quad \frac{\sigma_A^\alpha(\omega^\alpha \eta_5^\alpha + \rho^\alpha \eta_6^\alpha)}{(\mu_A + \sigma_A)(\mu_A^\alpha + \gamma_A^\alpha)} + \frac{\sigma_H^\alpha d\eta_1^\alpha \omega^\alpha}{(\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha)} + \frac{d\sigma_H^\alpha \sigma_A^\alpha [\omega^\alpha(\eta_2^\alpha \eta_4^\alpha - \eta_1^\alpha \eta_5^\alpha) + \rho^\alpha(\eta_3^\alpha \eta_4^\alpha - \eta_1^\alpha \eta_6^\alpha)]}{(\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha)(\mu_H^\alpha + \gamma_H^\alpha)(\mu_A + \sigma_A)(\mu_A^\alpha + \gamma_A^\alpha)\omega^\alpha} > 1.$$

Then the conditions of trace and determinant are proved, thus the others eigenvalues have negative real part. So that:  $|\arg \lambda_j| > \frac{\alpha\pi}{2}$  for all  $0 < \alpha \leq 1$ .

**Conclusion:** The disease-free equilibrium  $\psi_0$  of the model (3) is locally asymptotically stable whenever the condition (52) holds as well as  $R_0 < 1$  and it is unstable when  $R_0 > 1$ .  $\square$

**3.6. Global Stability of the Disease-Free Equilibrium.** The global asymptotically stability (GAS) of the disease-free state of the model is investigated using the theorem by [25, 26, 27].

So from the model (3) we have:

$$(53) \quad \begin{cases} \frac{dU}{dt} = F(U, Z), \\ \frac{dZ}{dt} = G(U, Z), \quad \text{with } G(U, 0) = 0. \end{cases}$$

where

- $U = (S_H, V_H, S_A)$  is the number of uninfected individuals, and
- $Z = (E_H, I_H, E_A, I_A, C_e)$  represents the number of infected individuals

Let  $U^*$  be the disease-free equilibrium (DFE) of the system  $\frac{dU}{dt} = F(U, 0)$ , and

$$U^* = \left( \frac{\Lambda_H^\alpha (\phi^\alpha + (1 - \kappa^\alpha) \mu_H^\alpha)}{\mu_H (\mu_H^\alpha + \phi^\alpha)}, \frac{\kappa^\alpha \Lambda_H^\alpha}{\mu_H^\alpha + \phi^\alpha}, \frac{\Lambda_A^\alpha}{\mu_A^\alpha} \right),$$

If  $R_0 < 1$  (which is locally asymptotically stable (LAS)), and the following two assumptions A1 and A2 hold, the Disease-Free Equilibrium (DFE) point  $\Phi_0$  of the model is guaranteed to be GAS:

- A1: For  $\frac{dU}{dt} = F(U, 0)$ ,  $U^*$  is globally GAS for the model (3) provided that  $R_0 < 1$  (LAS) and assumptions A1 and A2 hold.
- A2 :  $G(U, Z) = AZ - G^*(U, Z)$ ,  $G^*(U, Z) \geq 0$ ,  $\forall (U, Z) \in \Psi$ .

The region where the model makes biological sense is  $\Psi_0$ , and  $A = \frac{\partial G(\Phi_0)}{\partial Z}$  is an M-matrix (the nondiagonal entries are nonnegative).

The following theorem is true if the model equation (3) satisfies the above two requirements.

**Theorem 3.4.** *The disease-free equilibrium point,  $\Phi_0$  is globally asymptotically stability (GAS) for the model (3) provided that  $R_0 < 1$  locally asymptotically stable (LAS) and the conditions A1 and A2 hold.*

*Proof of theorem 3.4.* Let us show that the condition A1 and A2 hold when  $R_0 < 1$ , to do that, we need to show that  $U \rightarrow U^*$ .

$$(54) \quad F(U, 0) = \begin{cases} {}^C_0 D_t^\alpha S_H(t) = \Lambda_H^\alpha + \phi^\alpha V_H - \kappa^\alpha \Lambda_H^\alpha - \mu_H^\alpha S_H, \\ {}^C_0 D_t^\alpha V_H(t) = \kappa^\alpha \Lambda_H^\alpha - (\mu_H^\alpha + \phi^\alpha) V_H, \\ {}^C_0 D_t^\alpha S_A(t) = \Lambda_A^\alpha - \mu_A^\alpha S_A \end{cases}$$

The second and the third equation of the equation (54) are the  $\alpha$ 's order linear ODE's and we have their solution like following:

${}^C_0 D_t^\alpha S_H(t) = \Lambda_H^\alpha + \phi^\alpha V_H - \kappa^\alpha \Lambda_H^\alpha - \mu_H^\alpha S_H$ , using the Laplace transform

$$\begin{aligned} \mathcal{L}\{D_t^\alpha S_A(t)\}(W) &= \mathcal{L}\{\Lambda_A^\alpha - \mu_A^\alpha S_A(t)\}(W) \implies \\ (55) \quad \mathcal{L}\{D_t^\alpha S_A(t)\}(W) + \mathcal{L}\{\mu_A^\alpha S_A(t)\}(W) &= \mathcal{L}\{\Lambda_A^\alpha\} \implies \\ W^\alpha S_A(W) - D^{-(1-\alpha)} S_A(0) + \mu_A^\alpha S_A(W) &= \frac{\Lambda_A^\alpha}{W} \end{aligned}$$

At  $t = 0$   $D^{-(1-\alpha)} S_A(0) = 0$ . Then

$$(W^\alpha + \mu_A^\alpha) S_A(W) = \frac{\Lambda_A^\alpha}{W} \implies S_A(W) = \frac{\Lambda_A^\alpha}{W(W^\alpha + \mu_A^\alpha)}$$

Now by taking the Laplace inverse transform of  $S_A(W)$  and using the Mittag-Leffler function we obtain:

$$S_A(t) = \frac{\Lambda_A^\alpha}{\mu_A^\alpha} [1 - E_\alpha(-\mu_A^\alpha t^\alpha)] \quad \text{with } \mu_A^\alpha > 0$$

Then we have:  $S_A(t) \rightarrow \frac{\Lambda_A^\alpha}{\mu_A^\alpha}$  if  $t \rightarrow \infty$ .

By the same method we obtain:

$$V_H(t) = \frac{\kappa^\alpha \Lambda_H^\alpha}{\mu_H^\alpha + \phi^\alpha} [1 - E_\alpha(-(\mu_H^\alpha + \phi^\alpha) t^\alpha)] \quad \text{with } (\mu_H^\alpha + \phi^\alpha) > 0$$

Then we have:  $V_H(t) \rightarrow \frac{\kappa^\alpha \Lambda_H^\alpha}{\mu_H^\alpha + \phi^\alpha}$  if  $t \rightarrow \infty$ .

Now by substituting  $V_H(t)$  in the first equation of (54) yields:

$$(56) \quad D_t^\alpha S_H(t) = \Lambda_H^\alpha(1 - \kappa^\alpha) - \mu_H^\alpha S_H + \phi^\alpha \frac{\kappa^\alpha \Lambda_H^\alpha}{\mu_H^\alpha + \phi^\alpha} [1 - E_\alpha(-(\mu_H^\alpha + \phi^\alpha) t^\alpha)].$$

Let us take the Laplace transform of (56):

$$\begin{aligned} (57) \quad \mathcal{L}\{D_t^\alpha S_H(t)\}(W) &= \mathcal{L}\left\{\Lambda_H^\alpha(1 - \kappa^\alpha) - \mu_H^\alpha S_H + \phi^\alpha \frac{\kappa^\alpha \Lambda_H^\alpha}{\mu_H^\alpha + \phi^\alpha} [1 - E_\alpha(-(\mu_H^\alpha + \phi^\alpha) t^\alpha)]\right\}(W) \implies \\ \mathcal{L}\{D_t^\alpha S_H(t)\}(W) + \mathcal{L}\{\mu_H^\alpha S_H(t)\}(W) &= \mathcal{L}\{\Lambda_H^\alpha(1 - \kappa^\alpha)\} + \mathcal{L}\left\{\phi^\alpha \frac{\kappa^\alpha \Lambda_H^\alpha}{\mu_H^\alpha + \phi^\alpha} [1 - E_\alpha(-(\mu_H^\alpha + \phi^\alpha) t^\alpha)]\right\} \implies \\ W^\alpha S_H(W) - D^{-(1-\alpha)} S_H(0) + \mu_H^\alpha S_H(W) &= \frac{\Lambda_H^\alpha(1 - \kappa^\alpha)}{W} + \phi^\alpha \frac{\kappa^\alpha \Lambda_H^\alpha}{\mu_H^\alpha + \phi^\alpha} \left[\frac{1}{W} - \frac{W^{\alpha-1}}{W^\alpha + (\mu_H^\alpha + \phi^\alpha)}\right] \end{aligned}$$

At  $t = 0$   $D^{-(1-\alpha)} S_H(0) = 0$ .

Then

$$\begin{aligned}
 (58) \quad (W^\alpha + \mu_H^\alpha)S_H(W) &= \frac{\Lambda_H^\alpha(1 - \kappa^\alpha)}{W} + \phi^\alpha \frac{\kappa^\alpha \Lambda_H^\alpha}{\mu_H^\alpha + \phi^\alpha} \left[ \frac{1}{W} - \frac{W^{\alpha-1}}{W^\alpha + (\mu_H^\alpha + \phi^\alpha)} \right] \implies \\
 S_H(W) &= \frac{\Lambda_H^\alpha(1 - \kappa^\alpha)}{W(W^\alpha + \mu_H^\alpha)} + \phi^\alpha \frac{\kappa^\alpha \Lambda_H^\alpha}{(\mu_H^\alpha + \phi^\alpha)(W^\alpha + \mu_H^\alpha)W} - \frac{\phi^\alpha \kappa^\alpha \Lambda_H^\alpha}{(\mu_H^\alpha + \phi^\alpha)} \frac{1}{W^\alpha + \mu_H^\alpha} \times \frac{W^{\alpha-1}}{W^\alpha + (\mu_H^\alpha + \phi^\alpha)}
 \end{aligned}$$

Now by taking the Laplace Inverse Transform, we obtain

$$\begin{aligned}
 (59) \quad S_H(t) &= \frac{\Lambda_H^\alpha(1 - \kappa^\alpha)}{\mu_H^\alpha} [1 - E_\alpha(-\mu_H^\alpha t^\alpha)] + \frac{\phi^\alpha \kappa^\alpha \Lambda_H^\alpha}{\mu_H^\alpha(\mu_H^\alpha + \phi^\alpha)} [1 - E_\alpha(-\mu_H^\alpha t^\alpha)] \\
 &\quad - \frac{\phi^\alpha \kappa^\alpha \Lambda_H^\alpha}{(\mu_H^\alpha + \phi^\alpha)} \times t^{\alpha-1} E_{\alpha,\alpha}(-\mu_H^\alpha t^\alpha) \times E_{\alpha,1}[-(\mu_H^\alpha + \phi^\alpha)]
 \end{aligned}$$

$$\begin{aligned}
 (60) \quad \lim_{t \rightarrow \infty} S_H(t) &= \frac{\Lambda_H^\alpha(1 - \kappa^\alpha)}{\mu_H^\alpha} + \frac{\phi^\alpha \kappa^\alpha \Lambda_H^\alpha}{\mu_H^\alpha(\mu_H^\alpha + \phi^\alpha)} \\
 &= \frac{\Lambda_H^\alpha[\phi^\alpha + \mu_H^\alpha(1 - \kappa^\alpha)]}{\mu_H^\alpha(\mu_H^\alpha + \phi^\alpha)}
 \end{aligned}$$

Thus all points with respect to this conditions converge at

$$U^* = \left( \frac{\Lambda_H^\alpha(\phi^\alpha + (1 - \kappa^\alpha)\mu_H^\alpha)}{\mu_H^\alpha(\mu_H^\alpha + \phi^\alpha)}, \frac{\kappa^\alpha \Lambda_H^\alpha}{\mu_H^\alpha + \phi^\alpha}, \frac{\Lambda_A^\alpha}{\mu_A^\alpha} \right)$$

. Hence  $U^*$  is globally asymptotically stable.

For the next step, we have:

$$(61) \quad G(U, Z) = \begin{cases} G1(U, Z) = \left( \frac{\eta_1^\alpha I_H + \eta_2^\alpha I_A + \eta_3^\alpha C_e}{\Omega_H} \right) S_H + d \left( \frac{\eta_1^\alpha I_H + \eta_2^\alpha I_A + \eta_3^\alpha C_e}{\Omega_H} \right) V_H - (\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha) E_H \\ G2(U, Z) = \sigma_H^\alpha E_H - (\mu_H^\alpha + \gamma_H^\alpha) I_H, \\ G3(U, Z) = \left( \frac{\eta_4^\alpha I_H + \eta_5^\alpha I_A + \eta_6^\alpha C_e}{\Omega_A} \right) S_A - (\mu_A^\alpha + \sigma_A^\alpha) E_A, \\ G4(U, Z) = \sigma_A^\alpha E_A - (\mu_A^\alpha + \gamma_A^\alpha) I_A, \\ G5(U, Z) = \rho^\alpha I_A - \omega^\alpha C_e \end{cases}$$

We then obtain:

$$(62) \quad \frac{\partial G}{\partial Z} = \begin{bmatrix} -(\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha) & \frac{\eta_1^\alpha}{\Omega_H} S_H + d \frac{\eta_1^\alpha}{\Omega_H} V_H & 0 & \frac{\eta_2^\alpha}{\Omega_H} S_H + d \frac{\eta_2^\alpha}{\Omega_H} V_H & \frac{\eta_3^\alpha}{\Omega_H} S_H + d \frac{\eta_3^\alpha}{\Omega_H} V_H \\ \sigma_H^\alpha & -(\mu_H^\alpha + \gamma_H^\alpha) & 0 & 0 & 0 \\ 0 & \frac{\eta_4^\alpha}{\Omega_A} S_A & -(\mu_A^\alpha + \sigma_A^\alpha) & \frac{\eta_5^\alpha}{\Omega_A} S_A & \frac{\eta_6^\alpha}{\Omega_A} S_A \\ 0 & 0 & \sigma_A^\alpha & -(\mu_H^\alpha + \gamma_H^\alpha) & 0 \\ 0 & 0 & 0 & \rho^\alpha & -\omega^\alpha \end{bmatrix}$$

$$(63) \quad A = \frac{\partial G(U^*, 0)}{\partial Z} = \begin{bmatrix} -(\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha) & \Upsilon_1 & 0 & \Upsilon_2 & \Upsilon_3 \\ \sigma_H^\alpha & -(\mu_H^\alpha + \gamma_H^\alpha) & 0 & 0 & 0 \\ 0 & \eta_4^\alpha & -(\mu_A^\alpha + \sigma_A^\alpha) & \eta_5^\alpha & \eta_6^\alpha \\ 0 & 0 & \sigma_A^\alpha & -(\mu_H^\alpha + \gamma_H^\alpha) & 0 \\ 0 & 0 & 0 & \rho^\alpha & -\omega^\alpha \end{bmatrix}$$

Where:

$$(64) \quad \begin{aligned} \Upsilon_1 &= \frac{\eta_1^\alpha \phi^\alpha + \eta_1^\alpha \mu_H^\alpha (1 - \kappa^\alpha + d\kappa^\alpha)}{\phi^\alpha + \mu_H^\alpha} \\ \Upsilon_2 &= \frac{\eta_2^\alpha \phi^\alpha + \eta_2^\alpha \mu_H^\alpha (1 - \kappa^\alpha + d\kappa^\alpha)}{\phi^\alpha + \mu_H^\alpha} \\ \Upsilon_3 &= \frac{\eta_3^\alpha \phi^\alpha + \eta_3^\alpha \mu_H^\alpha (1 - \kappa^\alpha + d\kappa^\alpha)}{\phi^\alpha + \mu_H^\alpha} \end{aligned}$$

$$(65) \quad G^*(U, Z) = AZ - G(U, Z) = \begin{bmatrix} (\eta_1^\alpha + \eta_2^\alpha + \eta_3^\alpha)I_H \left(1 - \frac{S_H + dV_H}{\Omega_H} + \mu_H^\alpha \kappa^\alpha (d-1)\right) \\ 0 \\ (\eta_4^\alpha + \eta_5^\alpha + \eta_6^\alpha)I_H \left(1 - \frac{S_A}{\Omega_A}\right) \\ 0 \\ 0 \end{bmatrix}$$

Since all parameters are positives also we have  $\frac{S_H + dV_H}{\Omega_H} \ll 1$  and  $\mu_H^\alpha \kappa^\alpha (d-1) \ll 1$ . It's follows that  $G1 \geq 0$ , it's evident that  $G3 \geq 0$ .

Hence  $G^*(U, Z) \geq 0 \quad \forall (U, Z) \in \Psi$ .

Therefore the DFE point  $\Phi_0$  of the model (3) is globally asymptotically stable. End of the proof.  $\square$

### 3.7. Endemic Equilibrium Points EE.

Now we introduce the  $(S_H, E_H, V_H, I_H, S_A, E_A, I_A, C_e) \in \mathbb{R}_+^8$  disease. The model has an concordance endemic equilibrium point shown by  $E^* = (S_H^*, E_H^*, V_H^*, I_H^*, S_A^*, E_A^*, I_A^*, C_e^*)$ .

The Endemic Equilibrium point is the solution of the  $(S_H, E_H, V_H, I_H, S_A, E_A, I_A, C_e)$  model whose disease persist in the population of human, the population of animals and the environmental impact. We can calculate it well by equating each equation of the system (3) by zero.



Then

$$(66) \quad \left\{ \begin{array}{l} \Lambda_H^\alpha + \phi^\alpha V_H^* - \left( \frac{\eta_1^\alpha I_H^* + \eta_2^\alpha I_A^* + \eta_3^\alpha C_e^*}{\Omega_H} \right) S_H^* - \kappa^\alpha \Lambda_H^\alpha - \mu_H^\alpha S_H^* = 0, \\ \left( \frac{\eta_1^\alpha I_H^* + \eta_2^\alpha I_A^* + \eta_3^\alpha C_e^*}{\Omega_H} \right) S_H^* + d \left( \frac{\eta_1^\alpha I_H^* + \eta_2^\alpha I_A^* + \eta_3^\alpha C_e^*}{\Omega_H} \right) V_H^* - (\mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha) E_H^* = 0, \\ \kappa^\alpha (\Lambda_H^\alpha + E_H^*) - (\mu_H^\alpha + \phi^\alpha) V_H^* - d \left( \frac{\eta_1^\alpha I_H^* + \eta_2^\alpha I_A^* + \eta_3^\alpha C_e^*}{\Omega_H} \right) V_H^* = 0, \\ \sigma_H^\alpha E_H^* - (\mu_H^\alpha + \gamma_H^\alpha) I_H^* = 0, \\ \Lambda_A^\alpha - \left( \frac{\eta_4^\alpha I_H^* + \eta_5^\alpha I_A^* + \eta_6^\alpha C_e^*}{\Omega_A} \right) S_A^* - \mu_A^\alpha S_A^* = 0, \\ \left( \frac{\eta_4^\alpha I_H^* + \eta_5^\alpha I_A^* + \eta_6^\alpha C_e^*}{\Omega_A} \right) S_A^* - (\mu_A^\alpha + \sigma_A^\alpha) E_A^* = 0, \\ \sigma_A^\alpha E_A^* - (\mu_A^\alpha + \gamma_A^\alpha) I_A^* = 0, \\ \rho^\alpha I_A^* - \omega^\alpha C_e^* = 0 \end{array} \right.$$

$$(67) \quad \left\{ \begin{array}{l} S_H^* = \frac{[\Lambda_H(1 - \kappa^\alpha) + \phi^\alpha V_H^*] \Omega_H}{\mu_H^\alpha \Omega_H + (\eta_1 I_H^* + (\eta_2^\alpha + \eta_3^\alpha \rho^\alpha / \omega^\alpha) I_A^*)} \\ E_H^* = \frac{\mu_H^\alpha + \gamma_H^\alpha}{\sigma_H \alpha} I_H^* \\ V_H^* = \frac{\kappa^\alpha \Omega_H (\Lambda_H^\alpha \sigma_H^\alpha + \mu_H^\alpha + \gamma_H^\alpha)}{\Omega_H (\mu_H^\alpha + \phi^\alpha) + d (\eta_1 I_H^* + (\eta_2^\alpha + \eta_3^\alpha \rho^\alpha / \omega^\alpha) I_A^*)} \\ I_H^* = \frac{(\mu_A^\alpha + \gamma_A^\alpha) (\mu_A^\alpha + \sigma_A^\alpha) [\Omega_A \mu_A^\alpha + (\eta_5^\alpha + \eta_6^\alpha \rho^\alpha / \omega^\alpha) I_A^*] - \Lambda_A^\alpha \sigma_A^\alpha (\eta_5^\alpha + \eta_5^\alpha \rho^\alpha / \omega_A^\alpha)}{\eta_4^\alpha \Lambda_H^\alpha \sigma_H^\alpha - \eta_4^\alpha (\mu_A^\alpha + \gamma_A^\alpha) (\mu_A^\alpha + \sigma_A^\alpha)} \\ S_A^* = \frac{\Lambda_A}{\mu_A} - \frac{(\mu_A^\alpha + \gamma_A^\alpha) (\mu_A^\alpha + \sigma_A^\alpha)}{\mu_A^\alpha \sigma_A^\alpha} I_A^* \\ E_A^* = \frac{\mu_A^\alpha + \gamma_A^\alpha}{\sigma_A^\alpha} I_A^* \\ I_A^* = I_A^* \\ C_e^* = \frac{\rho^\alpha}{\omega^\alpha} I_A^* \end{array} \right.$$

**3.8. Global Stability of the Endemic Equilibrium Points:** The global stability of the Endemic Equilibrium  $E^* = (S_H^*, E_H^*, V_H^*, I_H^*, S_A^*, E_A^*, I_A^*, C_e^*)$  for the fractional order of the system model (3) is established following theorem as:

**Theorem 3.5.** *Let  $\alpha \in (0, 1]$ , and  $R_0 > 1$ . Then the endemic equilibrium  $E$  of the proposed epidemic model (3) of fractional order model is globally stable in the interior of  $\Psi$ .*

*Proof of theorem 3.5.* To prove the global stability of the point  $E^*$ , we consider the Volterra-type Lyapunov functional approach [28] to define a function

$L(t) : \varepsilon(t) = [S_H(t), E_H(t), V_H(t), I_H(t), S_A(t), E_A(t), I_A(t), C_e(t)]^T \longrightarrow \mathbb{R}$ , as

$$\begin{aligned}
 (68) \quad L(t) &= \frac{1}{a_1} (S_H - S_H^* - S_H^* \log \frac{S_H}{S_H^*}) + \frac{1}{a_2} (E_H - E_H^* - E_H^* \log \frac{E_H}{E_H^*}) \\
 &+ \frac{1}{a_3} (V_H - V_H^* - V_H^* \log \frac{V_H}{V_H^*}) + \frac{1}{a_4} (I_H - I_H^* - I_H^* \log \frac{I_H}{I_H^*}) \\
 &+ \frac{1}{a_5} (S_A - S_A^* - S_A^* \log \frac{S_A}{S_A^*}) + \frac{1}{a_6} (E_A - E_A^* - E_A^* \log \frac{E_A}{E_A^*}) \\
 &+ \frac{1}{a_7} (I_A - I_A^* - I_A^* \log \frac{I_A}{I_A^*}) + \frac{1}{a_8} (C_e - C_e^* - C_e^* \log \frac{C_e}{C_e^*})
 \end{aligned}$$

where

$$\begin{aligned}
 a_1 &= \lambda_H^\alpha + \mu_H^\alpha \\
 a_2 &= \mu_H^\alpha + \sigma_H^\alpha + \kappa^\alpha \\
 a_3 &= \mu_H^\alpha + \phi^\alpha + d\lambda_H^\alpha \\
 a_4 &= \mu_H^\alpha + \gamma_H^\alpha \\
 a_5 &= \lambda_A^\alpha + \mu_A^\alpha \\
 a_6 &= \mu_A^\alpha + \sigma_A^\alpha \\
 a_7 &= \mu_A^\alpha + \gamma_A^\alpha \\
 a_8 &= \omega^\alpha
 \end{aligned}$$

The function  $L(t)$  is defined, continuous and positive definite for all  $t \geq 0$ . It can be verified that the equality holds if and only if  $S_H = S_H^*, E_H = E_H^*, V_H = V_H^*, I_H = I_H^*, S_A = S_A^*, E_A = E_A^*, I_A = I_A^*, C_e = C_e^*$ .

The  $\alpha$  order of  $L(S_H, E_H, V_H, I_H, S_A, E_A, I_A, C_e)$  is calculate to show  $D_t^\alpha L \leq 0$  at the endemic equilibrium point.

$$\begin{aligned}
 (69) \quad D_t^\alpha L &= \frac{1}{a_1} \left( \frac{S_H - S_H^*}{S_H} \right) D_t^\alpha S_H + \frac{1}{a_2} \left( \frac{E_H - E_H^*}{E_H} \right) D_t^\alpha E_H + \frac{1}{a_3} \left( \frac{V_H - V_H^*}{V_H} \right) D_t^\alpha V_H \\
 &+ \frac{1}{a_4} \left( \frac{I_H - I_H^*}{I_H} \right) D_t^\alpha I_H + \frac{1}{a_5} \left( \frac{S_A - S_A^*}{S_A} \right) D_t^\alpha S_A + \frac{1}{a_6} \left( \frac{E_A - E_A^*}{E_A} \right) D_t^\alpha E_A \\
 &+ \frac{1}{a_7} \left( \frac{I_A - I_A^*}{S_A} \right) D_t^\alpha I_A + \frac{1}{a_8} \left( \frac{C_e - C_e^*}{C_e} \right) D_t^\alpha C_e
 \end{aligned}$$

By substituting, and on simplification using the endemic state condition of model (3), we have from Eq. (69) as:

$$\begin{aligned}
 (70) \quad D_t^\alpha L &= -\frac{(S_H - S_H^*)^2}{S_H} - \frac{(E_H - E_H^*)^2}{E_H} - \frac{(V_H - V_H^*)^2}{V_H} - \frac{(I_H - I_H^*)^2}{I_H} - \frac{(S_A - S_A^*)^2}{S_A} \\
 &- \frac{(E_A - E_A^*)^2}{E_A} - \frac{(I_A - I_A^*)^2}{S_A} - \frac{(C_e - C_e^*)^2}{C_e}
 \end{aligned}$$

From the above calculation we can see that  $D_t^\alpha L \leq 0$

We note that if  $R_0 > 1$ , then the right-hand side of Eq. (70) is negative and it is equal to zero if  $S_H = S_H^*, E_H = E_H^*, V_H = V_H^*, I_H = I_H^*, S_A = S_A^*, E_A = E_A^*, I_A = I_A^*, C_e = C_e^*$ .

According to the LaSalle's invariance principle [29, 30], and

[28], we know that all solutions in  $\Psi$  converge to  $E^*$ . Therefore, the endemic state of the model (3) is globally asymptotically stable when  $R_0 > 1$  [31]. This completes the proof of (3.5).  $\square$

TABLE 2. Sensitivity indices for  $R_0$ .

<b>Parameter</b>	<b>Index</b>
$\mu_A$	-0.0779
$\mu_H$	-0.1700
$\eta_1$	0.0332
$\eta_4$	0.1430
$\eta_5$	0.4223
$\eta_6$	0.2585
$\sigma_A$	0.0313
$\sigma_H$	0.1213
$\kappa$	-0.1254
$\alpha_A$	-0.7772
$\alpha_H$	-0.0979
$\rho$	0.2585
$\phi$	-0.0571
$d$	0.0098
$\omega$	-0.4015

TABLE 3. Descriptions and values of parameters in model.

Parameter	Value	Interpretation	Source
$\Lambda_H$	Recruitment rate into the susceptible human population	36	[4], [5]
$\Lambda_A$	Recruitment rate into the susceptible animal population	200	[5]
$\mu_A$	Animal natural mortality rate	0.015	Estimated
$\mu_H$	Human natural mortality rate	0.04	Estimated
$\eta_1, \eta_2, \eta_3$	Humans infection rate from $I_H, I_A,$ and $C_e,$ respectively	0.35, 0.55, 0.999	[5]
$\sigma_A$	Animal incubation period	0.38	Estimated
$\sigma_H$	Human incubation period	0.38	Estimated
$\kappa$	Human vaccination rate	0.8	Estimated
$\alpha_A$	Animal disease-related death rate	0.25	Estimated
$\alpha_H$	Human disease-related death rate	0.05	[4]
$\rho$	Dairy products production rate	0.6	Estimated
$\phi$	Human loss rate of immunity	0.03	Estimated
$d$	The human efficacy of the vaccine	0.5	Estimated
$\omega$	The decay rate in the contaminated environment	0.7	Estimated
$\eta_4, \eta_5, \eta_6$	Animals infection rate from $I_H, I_A,$ and $C_e,$ respectively	0.25, 0.7, 0.5	[5], Estimated, Estimated

## 4. NUMERICAL RESULTS AND DISCUSSION

**4.1. The Basic reproduction number  $R_0$  without vaccination.** Let us denote  $R_0$  without vaccination as  $R_0^*$ .

Using the parameters in table 3 and Maple software for computations,  $R_0^*$  and  $R_0$  are given as follow:

$$R_0^* = \frac{R_1}{2} + \frac{\sqrt{R_2^2 + 4R_3}}{2}$$

where

$$R_1 = \frac{\beta_1 \sigma_H}{(\mu_H + \sigma_H)(\mu_H + \alpha_H)} + \frac{\beta_5 \sigma_A}{(\mu_A + \sigma_A)(\mu_A + \alpha_A)} + \frac{\beta_6 \rho \sigma_A}{(\mu_A + \alpha_A)(\mu_A + \sigma_A) \omega}$$

$$R_2 = \frac{\beta_1 \sigma_H}{(\mu_H + \sigma_H)(\mu_H + \alpha_H)} - \frac{\beta_5 \sigma_A}{(\mu_A + \sigma_A)(\mu_A + \alpha_A)} - \frac{\beta_6 \rho \sigma_A}{(\mu_A + \alpha_A)(\mu_A + \sigma_A) \omega}$$

$$R_3 = \frac{\sigma_A \mu_H (\beta_2 \omega + \beta_3 \rho) \beta_4 \sigma_H}{\mu_H (\mu_H + \sigma_H) (\mu_H + \alpha_H) (\mu_A + \sigma_A) (\mu_A + \alpha_A) \omega}$$

•  $R_0^* = 7.4296$

- $R_0 = 4.9574$

From the above calculations, it indicates that the best way in minimizing the bovine tuberculosis is to use more vaccination in both human and animal populations.

**4.1.1. Herd Immunity Threshold  $H_1$ :** We are therefore motivated to determine the number of people or animals that should receive vaccinations when  $R_0^* = 7.4296$  based on the previously mentioned computations.

$$H_1 = 1 - \frac{1}{R_0^*} = 0.86$$

This shows that if  $R_0^* = 7.4296$ , then 86% of individuals and animals should receive vaccination.

**4.2. Sensitivity Analysis of Basic Reproduction Number  $R_0$ .** Understanding how each parameter affects the model output and its impact on the spread of disease throughout the population is made possible by the sensitivity analysis of  $R_0$  [32]. Using the normalized forward sensitivity analysis index employed by Silva [33] and Torres [32], we undertake sensitivity analysis of  $R_0$ .

$$\Psi_{\beta}^{R_0} = \left( \frac{\partial R_0}{\partial \beta} \right) \left( \frac{\beta}{R_0} \right),$$

is the formula for the normalized forward sensitivity index of variable  $\beta$  with respect to the fundamental reproduction number  $R_0$ .

Table 2 lists the sensitivity index of each parameter to the fundamental reproduction number  $R_0$  using estimated parameters and information from related literature.

According to sensitivity analysis, the evolution of bTB are driven by animal infection rates associated with the consumption of dairy products  $\eta_6$  and contact rates with infectious animals  $\eta_5$  as well as animal infection rates associated with the contact of infectious humans  $\eta_4$ , the animal and human incubation period,  $\sigma_A$  and  $\sigma_H$  respectively. The rate of making dairy products  $\rho$  is typically the most sensitive characteristic. The fundamental reproduction number  $R_0$  increases by 0.018% for every 10% increase in dairy products. The fundamental reproduction number  $R_0$  decreases as a result of an increase in the animal mortality rate owing to disease  $\alpha_A$ , the animal natural mortality rate  $\mu_A$ , the human disease-induced death rate  $\alpha_H$ , the human natural mortality rate  $\mu_H$ , the decay rate of dairy products  $\omega$ , and the human vaccination rate.

We also note that, the human infection rates  $\eta_2$  and  $\eta_3$  from infectious animals and contaminated environment have no effect on the fundamental reproduction number  $R_0$ .

**4.3. Numerical simulation.** By taking into account the variables that influence the dynamics of bTB transmission, we address the evolution of bTB in the human and animal populations in this section. We use both estimated parameters and ones from the pertinent literature, as shown in Table 3 to illustrate the behavior of the model for different fractional order  $1 < \alpha \leq 1$  and different values for those parameters.






FIGURE 2. Dynamics of bTB in human population (a) and animal population (b) for  $\alpha = 65$ .

As seen in Figure 2, the number of susceptible people and animals decreases after contracting bTB from infected people and animals as well as after ingesting infected dairy products. But the people in the susceptible class decrease more than the case of animals, this is because of the vaccination for the human population. They both migrate into the exposed class and eventually into the infectious class.


Figures 3a, (3b), and (3c) show the effect of varying  $\alpha$  on susceptible humans, susceptible animals and vaccinated humans respectively. The animal population is more infected than the human population as shown in figure 4, this can be explain by the fact that only humans receive vaccination.



(A)




(B)




(C)

FIGURE 3. Variation of  $\alpha$  for susceptible humans (a), animals (b), and vaccinated humans (c) population.






(A)




(B)

FIGURE 4. Variation of  $\alpha$  for infected humans (a) and infected animal(b) population.

4.3.1. *Impact of vaccination rate on infected humans and animals.*



(A)



(B)

FIGURE 5. Variation of  $\kappa$  for infected humans (a) and infected animal(b) population.

Figure 5 illustrates the outcomes of a numerical simulation carried out by varying the vaccination rate  $\kappa$  for human population while maintaining the other parameters constant. The simulation results clearly demonstrate that the plotted graphs show a downward trend as the vaccination rate  $\kappa$  increases for human population, but no significant effect for the animal population. This suggests that when the vaccination rate  $\kappa$  rises, the number of infected people decreases.

Consequently, it is crucial for the government and livestock farming experts to advise breeders to promptly vaccinate people and animals and put infected animals under quarantine as soon as they exhibit symptoms. By taking this measure, the spread of infection can be mitigated, leading to better human health and improved animal breeding outcomes.

**4.3.2. Investigating the influence of the decay rate on the contaminated environment.** Figure 6 illustrates the outcomes of a numerical simulation carried out by varying the rate of decaying  $\omega$  for contaminated environment (dairy products and meat) while maintaining the other parameters fixed. The findings demonstrate a clear correlation between the reduction of the decay rate and an increase of infectious humans and animals. Consequently, it can be inferred that elevating the decay rate significantly aids in eradicating the disease from both human and animal population.




FIGURE 6. Variation of  $\omega$  for infected humans (a) and infected animal (b) population.

**4.3.3. Impact of the animal infection rate from infected animals.**




FIGURE 7. Variation of  $\eta_5$  for infected humans (a) and infected animal(b) population .

The numerical result achieved by altering the animal infection rate  $\eta_5$  from infected animals while maintaining other parameters constant is shown in Figure 7. The quantity of infected animals and humans is increased after the value of  $\eta_5$  is raised from 0.5 to 0.8. The proportion of diseased animals and humans are larger at  $\eta_5 = 0.8$  than at other times. Overall, the numerical outcomes demonstrate that raising the animal infection rate value causes an increase in the number of infected animals and humans. To stop the disease from spreading, all interested parties and policy makers must consider ways to reduce the animal infection rate  $\eta_5$  from infected animals by putting the infectious animals under quarantine.

## 5. SUMMERY AND CONCLUSION

We developed a fractional-order mathematical model in this study to simulate the progression of bovine tuberculosis in the presence of vaccination and a contaminated environment. The model was developed and described in Section (2). In Section (3), we looked at the qualitative behaviors of the model by finding the feasible region, the positivity of the solution, equilibrium points, and examining their local and global stability. We also looked at the fundamental reproduction number of the model. Through sensitivity analysis of the basic reproduction number, the traits that have a substantial impact on the management of bovine TB have been found. In Section (4), the results of the numerical simulation are examined. In this numerical simulation, we investigated the influence of the parameters  $\kappa$ ,  $\omega$ , and  $\eta_5$  on the fractional order model. As a result of this analysis, we can draw the conclusion that increasing the vaccination rate  $\kappa$  of both the human and animal populations will greatly slow the spread of the bovine TB illness in both those populations. Accordingly, bovine TB management tries to reduce the disease's infection in both human and animal populations based on the study's findings. In this case, lowering the animal infection rate from infected animals, while increasing the decay rate of the polluted environment, and increasing the human population's vaccination rate, ought to aid in disease control.

## CONFLICT OF INTERESTS

The authors declare that there is no conflict of interests.

## REFERENCES

- [1] World Health Organization, Qu'est-ce qui entrave la lutte contre la tuberculose en Afrique? (2022). <https://www.afro.who.int/fr/news/quest-ce-qui-entrave-la-lutte-contre-la-tuberculose-en-afrique>.
- [2] D. Otoo, S. Osman, S.A. Poku, et al. Dynamics of tuberculosis (TB) with drug resistance to first-line treatment and leaky vaccination: a deterministic modelling perspective, *Comput. Math. Methods Med.* 2021 (2021), 5593864. <https://doi.org/10.1155/2021/5593864>.
- [3] World Health Organization, WHO and The Union organize landmark consultation to galvanize action against Zoonotic TB, (2016), <https://www.who.int/news/item/16-04-2016-who-and-the-union-organize-landmark-consultation-to-galvanize-action-against-zoonotic-tb>.

- [4] S. Liu, A. Li, X. Feng, et al. A dynamic model of human and livestock tuberculosis spread and control in Urumqi, Xinjiang, China, *Comput. Math. Methods Med.* 2016 (2016), 3410320. <https://doi.org/10.1155/2016/3410320>.
- [5] T. Shirima Sabini, J. Ismail Irunde, D. Kuznetsov, Modeling the transmission dynamics of bovine tuberculosis, *Int. J. Math. Math. Sci.* 2020 (2020), 7424075. <https://doi.org/10.1155/2020/7424075>.
- [6] D. Otoo, G.T. Tilahun, S. Osman, et al. Modeling the dynamics of tuberculosis with drug resistance in North Shoa Zone, Oromiya Regional State, Ethiopia, *Commun. Math. Biol. Neurosci.* 2021 (2021), 12. <https://doi.org/10.28919/cmbn/5163>.
- [7] M. de Garine-Wichatitsky, A. Caron, R. Kock, et al. A review of bovine tuberculosis at the wildlife–livestock–human interface in sub-Saharan Africa, *Epidemiol. Infect.* 141 (2013), 1342–1356. <https://doi.org/10.1017/s0950268813000708>.
- [8] S.W. Dejene, I.M.A. Heitkönig, H.H.T. Prins, et al. Correction: Risk factors for bovine tuberculosis (bTB) in cattle in Ethiopia, *PLoS ONE.* 12 (2017), e0176654. <https://doi.org/10.1371/journal.pone.0176654>.
- [9] F.C. Blanco, C.J. Queval, F.R. Araujo, et al. Editorial: Recent advances in bovine tuberculosis, *Front. Vet. Sci.* 9 (2022), 907353. <https://doi.org/10.3389/fvets.2022.907353>.
- [10] M. Good, D. Bakker, A. Duignan, et al. The history of in vivo tuberculin testing in bovines: tuberculosis, a “one health” issue, *Front. Vet. Sci.* 5 (2018), 59. <https://doi.org/10.3389/fvets.2018.00059>.
- [11] S. Srinivasan, A.J. Conlan, L.A. Easterling, et al. A meta-analysis of the effect of bacillus calmette-guérin vaccination against bovine tuberculosis: is perfect the enemy of good?, *Front. Vet. Sci.* 8 (2021), 637580. <https://doi.org/10.3389/fvets.2021.637580>.
- [12] H. Ahmad, T.A. Khan, P.S. Stanimirović, et al. Modified variational iteration algorithm-II: convergence and applications to diffusion models, *Complexity.* 2020 (2020), 8841718. <https://doi.org/10.1155/2020/8841718>.
- [13] G.T. Tilahun, G.A. Wolle, M. Tofik, Eco-epidemiological model and analysis of potato leaf roll virus using fractional differential equation, *Arab J. Basic Appl. Sci.* 28 (2021), 41–50. <https://doi.org/10.1080/25765299.2020.1865621>.
- [14] Y. Chen, F. Liu, Q. Yu, et al. Review of fractional epidemic models, *Appl. Math. Model.* 97 (2021), 281–307. <https://doi.org/10.1016/j.apm.2021.03.044>.
- [15] K. Diethelm, A fractional calculus based model for the simulation of an outbreak of dengue fever, *Nonlinear Dyn.* 71 (2012), 613–619. <https://doi.org/10.1007/s11071-012-0475-2>.
- [16] A. Apelblat, Differentiation of the Mittag-Leffler functions with respect to parameters in the Laplace transform approach, *Mathematics.* 8 (2020), 657. <https://doi.org/10.3390/math8050657>.
- [17] G.T. Tilahun, G.A. Wolle, M. Tofik, Eco-epidemiological model and analysis of potato leaf roll virus using fractional differential equation, *Arab J. Basic Appl. Sci.* 28 (2021), 41–50. <https://doi.org/10.1080/25765299.2020.1865621>.

- [18] H. Kheiri, M. Jafari, Optimal control of a fractional-order model for the HIV/AIDS epidemic, *Int. J. Biomath.* 11 (2018), 1850086. <https://doi.org/10.1142/s1793524518500869>.
- [19] O. Diekmann, J.A.P. Heesterbeek, J.A.J. Metz, On the definition and the computation of the basic reproduction ratio  $R_0$  in models for infectious diseases in heterogeneous populations, *J. Math. Biol.* 28 (1990), 365–382. <https://doi.org/10.1007/bf00178324>.
- [20] S. Osman, O.D. Makinde, A mathematical model for coinfection of listeriosis and anthrax diseases, *Int. J. Math. Math. Sci.* 2018 (2018), 1725671. <https://doi.org/10.1155/2018/1725671>.
- [21] D. Otoo, I.O. Abeasi, S. Osman, et al. Mathematical modeling and analysis of the dynamics of hepatitis B with optimal control, *Commun. Math. Biol. Neurosci.* 2021 (2021), 43. <https://doi.org/10.28919/cmbn/5733>.
- [22] P. van den Driessche, J. Watmough, Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, *Math. Biosci.* 180 (2002), 29–48. [https://doi.org/10.1016/s0025-5564\(02\)00108-6](https://doi.org/10.1016/s0025-5564(02)00108-6).
- [23] J.I. Irunde, L.S. Luboobi, Y. Nkansah-Gyekye, Modeling the effect of tobacco smoking on the in-host dynamics of HIV/AIDS, *J. Math. Comput. Sci.* 6 (2016), 406–436.
- [24] S. Osman, O.D. Makinde, D.M. Theuri, Mathematical modelling of listeriosis epidemics in animal and human population with optimal control, *Tamk. J. Math.* 51 (2020), 261–287. <https://doi.org/10.5556/j.tkjm.51.2020.2860>.
- [25] C. Castillo-Chavez, B. Song, Dynamical models of tuberculosis and their applications, *Math. Biosci. Eng.* 1 (2004), 361–404. <https://doi.org/10.3934/mbe.2004.1.361>.
- [26] S. Osman, G.T. Tilahun, S.D. Alemu, et al. Analysis of the dynamics of rabies in North Shewa, Ethiopia, *Italian J. Pure Appl. Math* 48 (2022), 877–902.
- [27] S. Osman, H.A. Togbenon, D. Otoo, Modelling the dynamics of campylobacteriosis using nonstandard finite difference approach with optimal control, *Comput. Math. Methods Med.* 2020 (2020), 8843299. <https://doi.org/10.1155/2020/8843299>.
- [28] P.A. Naik, J. Zu, M.B. Ghori, et al. Modeling the effects of the contaminated environments on COVID-19 transmission in India, *Results Phys.* 29 (2021), 104774. <https://doi.org/10.1016/j.rinp.2021.104774>.
- [29] Z. Shuai, P. van den Driessche, Global stability of infectious disease models using Lyapunov functions, *SIAM J. Appl. Math.* 73 (2013), 1513–1532. <https://doi.org/10.1137/120876642>.
- [30] D. Otoo, I.O. Abeasi, S. Osman, et al. Stability analysis and modeling the dynamics of hepatitis B with vaccination compartment, *Italian J. Pure Appl. Math* 48 (2022), 903–927.
- [31] S. Osman, D. Otoo, C. Sebil, et al. Bifurcation, sensitivity and optimal control analysis of modelling Anthrax-Listeriosis co-dynamics, *Commun. Math. Biol. Neurosci.* 2020 (2020), 98. <https://doi.org/10.28919/cmbn/5161>.

- [32] C.J. Silva, D.F.M. Torres, Optimal control for a tuberculosis model with reinfection and post-exposure interventions, *Math. Biosci.* 244 (2013), 154–164. <https://doi.org/10.1016/j.mbs.2013.05.005>.
- [33] N. Chitnis, J.M. Hyman, J.M. Cushing, Determining important parameters in the spread of malaria through the sensitivity analysis of a mathematical model, *Bull. Math. Biol.* 70 (2008), 1272–1296. <https://doi.org/10.1007/s11538-008-9299-0>.